Publication | Closed Access
Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study
17
Citations
0
References
2019
Year
PsychiatryMood SymptomPsychotropic MedicationPharmacologyDepressionPsychopharmacologyNeuropharmacologySocial SciencesPharmacotherapyMental HealthLong-term SafetyMedicinePsychopathologyEsketamine Nasal SprayTreatment-resistant Depression
No additional data available for this publication yet. Check back later!